journals.plos.org /3 days ago

GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

by Jingyi Ke, Zi Wang, Zhengyang Guo, Guangshuo Ou, Wei Li Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhib...

Read source
bioengineer.org /3 weeks ago

Rare EGFR Mutation Shows Primary Resistance to Afatinib in Lung Cancer Case

A case report documents rapid progression and death in a lung cancer patient with a rare EGFR PACC mutation who showed primary resistance to afatinib.

Read source
bioengineer.org /1 week ago

Patient Survived Twenty Months After Small-Cell Transformation of Resected Lung Adenocarcinoma

A clinical case report documents a 48-year-old woman with EGFR-mutant lung adenocarcinoma who developed small-cell lung cancer transformation four years after surgery and survived...

Read source
journals.plos.org /1 month ago

Role of the m<sup>6</sup>A methyltransferase Mettl16 in <i>Drosophila</i> development

by Penghui Song, Lijuan Ma, Dong Yan N6-methyladenosine (m6A), one of the most abundant chemical modifications on RNA, is installed by METTL3 and several other methyltransferases,...

Read source
bioengineer.org /1 week ago

Meta-Analysis Assesses Targeted Therapies for MET-Altered Non-Small Cell Lung Cancer

A systematic review and meta-analysis of 25 clinical trials found that MET tyrosine kinase inhibitors achieved a 49 percent objective response rate in MET-altered non-small cell lu...

Read source
asianscientist.com /1 month ago

This Molecular Switch Helps Triple-Negative Breast Cancers Resist Treatment

Researchers uncover how the long non-coding RNA Smyca helps triple-negative breast cancer cells repair DNA damage and survive treatment.

Read source
journals.plos.org /1 month ago

Hyper-mutational processes provide a head-start for weak cancer drivers: Explaining atypical <i>KRAS</i> var...

by Michael D. Nicholson, Ian Tomlinson Hypermutant cancers frequently contain atypical driver gene variants, which may provide sub-optimal oncogenic advantages. The reason why wea...

Read source
qchron.com /1 week ago

PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FD...

PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor respo...

Read source
qchron.com /4 weeks ago

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-muta...

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G1...

Read source
bioengineer.org /1 month ago

Rare EGFR mutation sharply raises lung cancer risk in large genetic study

An observational study of 3.3 million research participants found that inherited EGFR T790M was associated with 25-fold higher lung cancer risk overall and more than 60-fold risk a...

Read source
bioengineer.org /4 days ago

RNA Modification Regulates Melanoma Progression and Immune Response in Preclinical Studies

A comprehensive scientific review synthesizes preclinical evidence revealing how m6A RNA modification governs melanoma progression, immune escape, and response to checkpoint immuno...

Read source
pharmexec.com /1 week ago

<![CDATA[Adjusting for Tumor Mutations: Q&A with Dr. Brian Corgiat]]>

Read source
medicalxpress.com /1 month ago

One gene helps drive growth in two childhood brain tumor groups that lack targeted therapies

Targeting KDM2B or downstream protein complexes it recruits may exploit a vulnerability in high-risk medulloblastoma subgroups that currently lack targeted therapies, according to...

Read source
fightaging.org /3 weeks ago

Splicing Factor SRSF1 Overexpression Produces a More Youthful Transcriptome and Slows Aging in Mice

Researchers are engaged in finding alternative ways to induce the desirable epigenetic rejuvenation produced by exposing cells to the Yamanaka factors, without the risk of losing c...

Read source
biopharmadive.com /1 week ago

PepGen soars on promising early data for muscular dystrophy drug

While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics. 

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.